Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition

Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition

Background: SGLT2i reduce cardiac hypertrophy, but underlying mechanisms remain unknown. Here we explore a role for serine/threonine kinases (STK) and sodium hydrogen exchanger 1(NHE1) activities in SGLT2i effects on cardiac hypertrophy. Methods: Isolated hearts from db/db mice were perfused with 1 ...

Full description

Bibliographic Details
Main Authors: Sha Chen, Kenneth Overberg, Zakiya Ghouse, Markus W. Hollmann, Nina C. Weber, Ruben Coronel, Coert J. Zuurbier
Format: Article
Language:English
Published: Elsevier 2024-05-01
Series:Biomedicine & Pharmacotherapy
Subjects:
sodium glucose co-transporter 2 inhibitors (SGLT2i)
sodium hydrogen exchanger 1 (NHE1)
p90 ribosomal S6 Kinase (RSK)
hypertrophy
Aurora
FoxO pathways
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332224003615

Internet

http://www.sciencedirect.com/science/article/pii/S0753332224003615

Similar Items